Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for reduced levels of dasabuvir, ombitasvir, and paritaprevir
Drug 1
Drug 1 dose
200 mg BID
Drug 1 effect
Nevirapine AUC decreased 27% (at week 4); Nevirapine AUC no significant change (at week 10)Nevirapine AUC with rifampicin approximates nevirapine baseline without rifampicin at week 10.
Drug 2 effect
Not studied (may decrease paritaprevir levels)
Clinical Effects
Potential decrease in HCV agent efficacy
Management
Use alternative agents
Import ID
604
